Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Moore, K.; Colombo, N.; Scambia, G.; Kim, Byoung-Gie; Oaknin, A.; Friedlander, M.; Lisyanskaya, A.; Floquet, A.; Leary, A.; Sonke, G.; Gourley, C.; Banerjee, Susana; Oza, A.; González-Martín, A.; Aghajanian, C.; Bradley, W.; Mathews, C.; F. Liu, Joyce; Lowe, E.; Bloomfield, R.; DiSilvestro, P.

doi:10.1056/NEJMoa1810858

Public

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Shared by NobleBlocks on Oct 21, 2018 • 12:00 AM UTC

Authors:

K. Moore

N. Colombo

G. Scambia

Abstract

BACKGROUND Most women with newly diagnosed advanced ovarian cancer have a relapse within 3 years after standard treatment with surgery and platinum‐based chemotherapy. The benefit of the oral poly(adenosine diphosphate–ribose) polymerase inhibitor olaparib in relapsed disease has been well establish...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!